These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 1648825)

  • 1. Fluorinated pyrimidines: a new change for old drugs.
    King DH
    Transplant Proc; 1991 Jun; 23(3 Suppl 3):168-70. PubMed ID: 1648825
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical aspects and management of cytomegalovirus infection.
    Sissons JG; Carmichael AJ
    J Infect; 2002 Feb; 44(2):78-83. PubMed ID: 12076065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New inhibitors of human cytomegalovirus (HCMV) on the horizon.
    De Clercq E
    J Antimicrob Chemother; 2003 May; 51(5):1079-83. PubMed ID: 12697653
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant.
    Prentice HG; Kho P
    Bone Marrow Transplant; 1997 Jan; 19(2):135-42. PubMed ID: 9116610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks.
    Fourel I; Hantz O; Watanabe KA; Jacquet C; Chomel B; Fox JJ; Trepo C
    Antimicrob Agents Chemother; 1990 Mar; 34(3):473-5. PubMed ID: 2334160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral activity of FIAU (1-[2'deoxy-2'-fluoro-1-beta-D-arabinofuranosyl]-5-iodo-uridine) on strains of cytomegalovirus sensitive and resistant to ganciclovir.
    Drew WL; Miner R; King D
    J Infect Dis; 1991 Jun; 163(6):1388-9. PubMed ID: 1645389
    [No Abstract]   [Full Text] [Related]  

  • 7. Tolerance and efficacy of ganciclovir in the treatment of cytomegalovirus infections in immunosuppressed patients.
    Ho WG; Winston DJ; Champlin RE
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3103-6. PubMed ID: 2539690
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytomegalovirus syndrome post-renal transplantation. Treatment with cytosine arabinoside.
    Fine RN; Malekzadeh M; Grushkin CM; Wright HT
    Calif Med; 1973 Mar; 118(3):46-9. PubMed ID: 4347632
    [No Abstract]   [Full Text] [Related]  

  • 9. Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
    Akesson-Johansson A; Lernestedt JO; Ringdén O; Lönnqvist B; Wahren B
    Bone Marrow Transplant; 1986 Dec; 1(2):215-20. PubMed ID: 2844334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation.
    Drobyski WR; Knox KK; Carrigan DR; Ash RC
    Transplantation; 1991 Jul; 52(1):155-7. PubMed ID: 1650043
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytomegalovirus infection in severe combined immunodeficiency: eradication with foscarnet.
    Walsh JE; Abinun M; Peiris JS; Appleton AL; Cant AJ
    Pediatr Infect Dis J; 1995 Oct; 14(10):911-2. PubMed ID: 8584325
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral therapies.
    Hallenberger S
    J Clin Virol; 2004 Apr; 30 Suppl 1():S23-5. PubMed ID: 15062765
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of cytomegalovirus infections in immunosuppressed patients].
    Michon C; Girard PM; Ngovan P; Simonpoli AM; Le Hoang P
    Ann Med Interne (Paris); 1988; 139(7):511-5. PubMed ID: 2854380
    [No Abstract]   [Full Text] [Related]  

  • 15. SAR studies on a novel series of human cytomegalovirus primase inhibitors.
    Chen X; Adrian J; Cushing T; Dimaio H; Liang L; Mayorga V; Miao S; Peterson MG; Powers JP; Spector F; Stein C; Wright M; Xu D; Ye Q; Jaen J
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2188-92. PubMed ID: 17329103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of microorganisms by pyrimidine nucleosides.
    Mehta BM; Hutchison DJ
    Ann N Y Acad Sci; 1975 Aug; 255():559-63. PubMed ID: 811152
    [No Abstract]   [Full Text] [Related]  

  • 17. Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact.
    Baldanti F; Gerna G
    J Antimicrob Chemother; 2003 Sep; 52(3):324-30. PubMed ID: 12888590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus studies in the treatment of congenital cytomegalovirus infections by cytosine arabinoside.
    Emödi G; Sartorius J; Just M; Rohner F; Bühler U
    Helv Paediatr Acta; 1972 Dec; 27(6):557-64. PubMed ID: 4346254
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis and biological activity of 1-(2-deoxy-2-C-fluoromethyl- and 2-C-hydroxymethylarabinofuranosyl)-cytosines.
    Yoshimura Y; Saitoh K; Ashida N; Sakata S; Sasaki T; Matsuda A
    Nucleic Acids Symp Ser; 1993; (29):33-4. PubMed ID: 8247781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a novel series of inhibitors of human cytomegalovirus primase.
    Cushing TD; Adrian J; Chen X; DiMaio H; Doughan B; Flygare J; Liang L; Mayorga V; Miao S; Mellon H; Peterson MG; Powers JP; Spector F; Stein C; Wright M; Xu D; Ye Q; Jaen J
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4879-83. PubMed ID: 16814545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.